Epidemiology and economic burden of osteoporosis in Switzerland by Svedbom, A. et al.
ORIGINAL ARTICLE
Epidemiology and economic burden
of osteoporosis in Switzerland
A. Svedbom & M. Ivergård & E. Hernlund & R. Rizzoli &
J. A. Kanis
Received: 27 March 2014 /Accepted: 17 June 2014 /Published online: 27 June 2014
# International Osteoporosis Foundation and National Osteoporosis Foundation 2014
Abstract
Summary This report describes the epidemiology, economic
burden and treatment of osteoporosis in Switzerland.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in in-
creased risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures are
associated with substantial pain and suffering, disability and
even death for the affected patients and substantial costs to
society. The aim of this report is to describe the epidemiology
and economic burden of fragility fractures as a consequence of
osteoporosis in Switzerland, as a detailed addition to the report
for the European Union (EU27): “Osteoporosis in the Euro-
pean Union: Medical Management, Epidemiology and Eco-
nomic Burden”.
Methods The literature on fracture incidence and costs of
fractures in Switzerland was reviewed and incorporated into
a model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk of
fracture were used to estimate treatment uptake and treatment
gap.
Results It was estimated that approximately 74,000 new fra-
gility fractures were sustained in Switzerland in 2010, com-
prising 14,000 hip fractures, 11,000 vertebral fractures,
13,000 forearm fractures and 36,000 other fractures (i.e. frac-
tures of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula,
sternum and other femoral fractures). The economic burden of
incident and previous fragility fractures was estimated at CHF
2,050 million for the same year. Incident fractures represented
76 % of this cost, long-term fracture care 21 % and pharma-
cological prevention 3 %. Previous and incident fractures also
accounted for 24,000 quality-adjusted life years (QALYs) lost
during 2010. When accounting for the demographic projec-
tions for 2025, the number of incident fractures was estimated
at 98,786 in 2025, representing an increase of 25,000 frac-
tures. Hip, clinical vertebral (spine), forearm and other frac-
tures were estimated to increase by 4,900, 3,200, 3,500 and
13,000, respectively. The burden of fractures in terms of costs
(excluding value of QALYs lost) in Switzerland in 2025 was
estimated to increase by 29 % to CHF 2,642 million. Though
the uptake of osteoporosis treatments increased from 2001, the
proportion of patients aged 50 or above who received treat-
ment remained at low levels in the past few years. The major-
ity of women at high fracture risk do not receive active
treatment.
Conclusions In spite of the high cost of osteoporosis, a sub-
stantial treatment gap and projected increase of the economic
burden driven by an aging population, the use of pharmaco-
logical prevention of osteoporosis is significantly less than
optimal, suggesting that a change in health care policy
concerning the disease is warranted.
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Introduction
Osteoporosis is characterized by reduced bone mass and dis-
ruption of bone architecture, resulting in increased risks of
fragility fractures which represent the main clinical conse-
quence of the disease. Fragility fractures are associated with
substantial pain and suffering, disability and even death for the
affected patients and substantial costs to society. The aim of
this report was to characterize the economic burden of osteo-
porosis in Switzerland in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Switzerland was reviewed and incorporated into a model
estimating the clinical and economic burden of osteoporotic
fractures in 2010. Details of the methods used are found in
Chapters 3 and 4 of the report “Osteoporosis in the European
Union: Medical Management, Epidemiology and Economic
Burden” [1], published in 2013 in Archives of Osteoporosis.
Epidemiology of osteoporosis in Switzerland
For the purpose of this report, the population at risk of oste-
oporosiswas considered to includemen andwomen≥50years.
The number of men and women ≥50 years of age amounted to
1,381,000 and 1,660,000, respectively, in Switzerland in 2010
(Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic criteria
applied to the femoral neck—was estimated at 460,000
(Table 2). There were 20.8 DXA units/million inhabitants,
and guidelines for the assessment and treatment of osteo-
porosis are available [2]. A country-specific FRAX model
Table 1 Population at risk: men and women over the age of 50 years in
Switzerland, 2010 [8]
Age (years) Women Men All
50–59 556,000 545,000 1,101,000
60–69 477,000 435,000 912,000
70–79 351,000 275,000 626,000
80–89 238,000 116,000 354,000
80+ 276,000 126,000 402,000
50+ 1,660,000 1,381,000 3,041,000
Table 2 Estimated
number of women and
men with osteoporosis
(defined as a T-score≤
−2.5 SD) in Switzerland
by age using female-de-
rived reference ranges at
the femoral neck, 2010
[9]
Age group (years) Women Men
50–54 19,026 7,525
55–59 24,384 8,540
60–64 34,320 12,992
65–69 47,874 15,614
70–74 54,684 12,636
75–79 58,125 11,639
80+ 130,272 20,916
50+ 368,685 89,862
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm and other fractures in Switzerland by age
Age (years) Fracture at the
Hip Vertebra Forearm Other
Women
50–54 17 113 319 110
55–59 54 76 232 471
60–64 67 328 743 259
65–69 139 157 485 475
70–74 247 260 718 700
75–79 473 721 759 996
80–84 1,169 1,635 1,449 1,987
85+ 2,937 1,390 1,135 4,933
Men
50–54 35 89 132 155
55–59 76 156 158 710
60–64 65 262 130 643
65–69 135 187 173 873
70–74 139 299 69 714
75–79 326 223 191 869
80–84 363 799 95 964
85+ 1,394 482 484 4,036
Table 4 Estimated number of incident fractures in Switzerland, 2010
Age (years) Fracture at the All fractures
Hip Vertebra Forearm Other
Women
50–74 1,735 2,697 6,305 6,460 17,197
75+ 8,886 4,871 4,528 16,092 34,376
Total 10,621 7,568 10,833 22,552 51,573
Men
50–74 1,233 2,306 1,588 8,205 13,333
75+ 1,980 1,089 693 5,523 9,286
Total 3,213 3,395 2,282 13,729 22,619
Men and women
50–74 2,968 5,002 7,893 14,665 30,529
75+ 10,866 5,960 5,221 21,615 43,663
Total 13,834 10,963 13,115 36,280 74,192
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is also available for the assessment of fracture risk (http://
www.shef.ac.uk/FRAX/).
Data on the incidence of hip, vertebral and forearm frac-
tures are available for Switzerland [3]. The incidence for
“other” fractures was derived as described in the EU27 report
[1] (Table 3).
The number of incident fractures in 2010 was estimated at
74,000 (Table 4). Incident hip, clinical spine, forearm and
other fractures were estimated at 14,000, 11,000, 13,000 and
36,000, respectively. Seventy percent of fractures occurred in
women.
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) and which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportion of individuals
who had suffered a fracture prior to 2010 was estimated at
2.0 % for hip and 2.7 % for clinical vertebral fractures. The
estimated proportions of men and women with prior hip and
vertebral fractures by age are presented in Table 5.
Table 5 Proportion of men and women (in %) with a prior hip or clinical
vertebral fracture in Switzerland, 2010
Age (years) Hip fracture Vertebral fracture
Women
50–54 0.0 0.2
55–59 0.2 0.6
60–64 0.5 1.5
65–69 1.0 2.3
70–74 1.9 3.1
75–79 3.5 5.0
80–84 6.6 8.7
85+ 15.8 14.0
Men
50–54 0.1 0.2
55–59 0.3 0.8
60–64 0.6 1.5
65–69 1.0 2.2
70–74 1.6 2.7
75–79 2.5 3.2
80–84 3.9 4.4
85+ 8.5 6.0
Table 6 Number of men and women in Switzerland with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50–74 8,187 17,256
75+ 36,424 39,174
Total 44,611 56,430
Men
50–74 7,134 14,881
75+ 9,936 9,943
Total 17,070 24,823
Men and women
50–74 15,320 32,137
75+ 46,360 49,116
Total 61,680 81,253
Table 7 Incidence (per 100,000) of causally related deaths in Switzer-
land within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral Other fracture
Women
50–54 397 516 10
55–59 641 788 19
60–64 842 978 27
65–69 1,056 1,157 40
70–74 1,416 1,461 64
75–79 1,740 1,681 109
80–84 1,985 1,757 221
85–89 2,637 2,050 462
90+ 3,011 1,698 1,047
Men
50–54 1,163 1,396 18
55–59 1,523 1,731 31
60–64 1,808 1,945 49
65–69 2,115 2,146 76
70–74 2,569 2,446 116
75–79 3,275 2,904 194
80–84 4,320 3,508 363
85–89 6,261 4,576 676
90+ 10,422 6,782 1,304
Table 8 The number of
deaths in men and wom-
en in Switzerland in the
first year after fracture
attributable to the frac-
ture event (causally re-
lated), 2010
Age (years) Fracture at the
Hip Vertebra Other
Women
50–74 21 32 3
75+ 210 85 113
Total 231 117 116
Men
50–74 27 49 6
75+ 124 43 43
Total 151 91 49
Men and women
50–74 49 81 9
75+ 334 127 156
Total 383 208 165
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In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 62,000 and 81,000, respectively
(Table 6). Note that fractures sustained in 2010 were not
included in the estimate.
The incidence of causally related deaths (per 100,000)
in the first year after fracture by age is presented in
Table 7. The number of causally related deaths in 2010
was estimated at 756 (Table 8). Hip, vertebral and other
fractures accounted for 383, 208 and 165 deaths, respec-
tively. Overall, approximately 61 % of deaths occurred in
women.
Cost of osteoporosis in Switzerland including
and excluding value of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that
occurred in 2010 (“first year costs”), (ii) cost of fractures
sustained prior to year 2010 but which still incurred
costs in 2010 (“long-term disability cost”) and (iii) cost
of pharmacological fracture prevention including admin-
istration and monitoring costs (“pharmacological fracture
prevention costs”). See Chapter 4 of the EU27 report [1]
for further details.
In Switzerland, the costs of hip, vertebral and wrist
fractures have been estimated to range from CHF 34,374
to 38,871, CHF 19,790 to 36,622 and CHF 7,000 to
25,454 depending on age, respectively [4]. One Swiss
franc (CHF) corresponds to 0.82 euro. Costs for other
fractures were estimated as described in Chapter 4 of the
EU27 report [1].
Long-term disability costs were estimated by multiply-
ing the yearly cost of residing in a nursing home (CHF
Table 9 One-year costs for relevant pharmaceuticals in Switzerland,
2010 [10]
Annual drug cost (CHF)
Alendronate 469
Risedronate 667
Ibandronate 489
Zoledronic acid 421
Raloxifene 629
Teriparatide 6,376
Table 10 Cost of osteoporosis (CHF) in Switzerland by age in men and
women, 2010
Age
(years)
First year
fracture cost
Long-term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 296,616,249 37,600,533 32,270,586 366,487,368
75+ 808,643,124 265,894,082 20,381,780 1,094,918,986
All 1,105,259,373 303,494,615 52,652,366 1,461,406,355
Men
50–74 253,595,483 38,772,184 5,137,307 297,504,974
75+ 206,776,516 81,831,119 2,264,754 290,872,389
All 460,371,999 120,603,303 7,402,061 588,377,364
Women and men
50–74 550,211,732 76,372,717 37,407,893 663,992,343
75+ 1,015,419,641 347,725,201 22,646,534 1,385,791,376
All 1,565,631,372 424,097,919 60,054,427 2,049,783,718
Table 11 Total cost (CHF) in
2010 by fracture site in men and
women in Switzerland. Note that
costs for fracture prevention,
therapy and monitoring are not
included
Age (years) Hip Spine Forearm Other All
Women
50–74 100,985,955 54,536,166 48,202,428 130,492,233 334,216,782
75+ 572,595,695 122,545,405 71,858,711 307,537,396 1,074,537,207
All 673,581,650 177,081,571 120,061,140 438,029,629 1,408,753,989
Men
50–74 82,322,724 45,552,418 11,995,901 152,496,625 292,367,667
75+ 144,371,747 23,210,565 12,025,998 108,999,327 288,607,635
All 226,694,470 68,762,983 24,021,898 261,495,951 580,975,303
Women and men
50–74 183,308,679 100,088,584 60,198,329 282,988,858 626,584,449
75+ 716,967,441 145,755,969 83,884,709 416,536,723 1,363,144,842
All 900,276,120 245,844,553 144,083,038 699,525,580 1,989,729,291
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74,294 [5]) with the simulated number of individuals
with prior fractures that had been transferred to a nursing
home due to the fracture.
Annual drug costs (CHF) for individual treatments are
shown in Table 9. In addition, it was assumed that patients
on treatment made an annual physician visit costing CHF 91
[5] and a DXA scan costing CHF 75 [5] every second year to
monitor treatment. The cost of osteoporosis in 2010 was
estimated at CHF 2,050 million (Table 10). First year costs,
subsequent year costs and pharmacological fracture preven-
tion costs amounted to CHF 1,566 million, CHF 424 million
and CHF 60 million, respectively. It is notable that pharma-
cological fracture prevention costs amounted to only 2.9 % of
the total cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were the most costly (CHF 900 million) followed by
other fractures (CHF 700 million), spine fractures (CHF 246
million) and forearm fractures (CHF 144 million) (Table 11
Fig. 1 Share (%) of fracture cost by fracture site in Switzerland. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Switzerland according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 415 1,832 2,247
Incident vertebral fractures 892 1,403 2,294
Incident forearm fractures 222 138 360
Incident other fractures 772 1,652 2,425
Prior hip fractures 1,282 4,872 6,154
Prior vertebral fractures 966 1,888 2,853
Total 4,549 11,785 16,334
Men
Incident hip fractures 299 471 770
Incident vertebral fractures 762 347 1,110
Incident forearm fractures 56 23 78
Incident other fractures 973 627 1,600
Prior hip fractures 1,114 1,470 2,584
Prior vertebral fractures 826 526 1,351
Total 4,029 3,464 7,493
Men and women
Incident hip fractures 714 2,303 3,017
Incident vertebral fractures 1,654 1,750 3,404
Incident forearm fractures 278 161 438
Incident other fractures 1,745 2,279 4,025
Prior hip fractures 2,395 6,343 8,738
Prior vertebral fractures 1,792 2,413 4,205
Total 8,578 15,249 23,827
Table 13 Value of lost QALYs (CHF) in men and women in Switzerland
in 2010
1×GDP/
capita
2×GDP/
capita
3×GDP/
capita
Incident hip fractures 205,296,216 410,592,432 615,888,648
Incident vertebral
fractures
231,621,487 463,242,975 694,864,462
Incident forearm
fractures
29,830,907 59,661,814 89,492,721
Incident other fractures 273,829,405 547,658,810 821,488,215
Prior hip fractures 594,528,606 1,189,057,213 1,783,585,819
Prior vertebral fractures 286,101,039 572,202,078 858,303,117
Total 1,621,207,660 3,242,415,321 4,863,622,981
Table 14 Population projections in Switzerland by age and sex [11]
Population
2010 2015 2020 2025
Women
50–59 556,000 646,000 689,000 642,000
60–69 477,000 481,000 536,000 624,000
70–79 351,000 402,000 425,000 433,000
80–89 238,000 220,000 235,000 275,000
90+ 38,000 59,000 66,000 66,000
Men
50–59 545,000 642,979 688,000 633,000
60–69 435,000 443,000 501,000 597,000
70–79 275,000 324,000 350,000 362,000
80–89 116,000 129,000 151,000 185,000
90+ 10,000 17,000 24,000 28,000
All
50–59 1,101,000 1,288,979 1,377,000 1,275,000
60–69 912,000 924,000 1,037,000 1,221,000
70–79 626,000 726,000 775,000 795,000
80–89 354,000 349,000 386,000 460,000
90+ 48,000 76,000 90,000 94,000
3,041,000 3,845,000
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and Fig. 1). Please note that costs for pharmacological fracture
prevention were not included given that they could not be
allocated to specific fracture sites.
The number of quality-adjusted life years (QALYs) lost
due to osteoporosis in 2010 was estimated at 23,827 (Ta-
ble 12). Prior fractures accounted for 54 % of the total loss
and 69 % of the loss occurred in women. The monetary value
of a QALY was varied between one and three times the gross
domestic product (GDP) per capita set at CHF 68,040. As-
suming a QALY is valued at two times the GDP/capita, the
total cost of the QALYs lost was estimated at CHF 3.24 billion
(Table 13).
When the cost of osteoporosis was combined with the
value of QALYs lost (valued at 2×GDP), the cost of osteopo-
rosis amounted to CHF 5.3 billion in Switzerland in 2010.
Incident fracture, prior fracture, pharmacological fracture
prevention and value of QALYs lost accounted for 30, 8, 1
and 61 %, respectively.
Economic burden of osteoporosis up to 2025
The population above 50 years of age is expected to
increase from 3.0 million in 2010 to 3.8 million in
2025, corresponding to an increase of 26 % (Table 14).
The total number of fractures was estimated to rise from
74,000 in 2010 to 99,000 in 2025 (Table 15), corre-
sponding to an increase of 33 %. Hip, clinical spine,
forearm and other fractures increased by 4,900, 3,200,
3,500 and 13,010, respectively. The increase in the num-
ber of fractures ranged from 27 to 36 %, depending on
Table 15 Projected annual num-
ber of incident fractures in 2010
and 2025 by fracture site and age
in men and women in Switzerland
Hip Spine Forearm Other
2010 2025 2010 2025 2010 2025 2010 2025
Women
50–74 1,735 2,127 2,697 3,344 6,305 7,814 6,460 7,938
75+ 8,886 11,530 4,871 6,121 4,528 5,687 16,092 20,897
All 10,621 13,657 7,568 9,466 10,833 13,501 22,552 28,834
Men
50–74 1,233 1,575 2,306 2,974 1,588 1,994 8,205 10,669
75+ 1,980 3,463 1,089 1,712 693 1,153 5,523 9,786
All 3,213 5,038 3,395 4,686 2,282 3,148 13,729 20,456
Women and men
50–74 2,968 3,702 5,002 6,318 7,893 9,808 14,665 18,607
75+ 10,866 14,994 5,960 7,834 5,221 6,841 21,615 30,683
All 13,834 18,695 10,963 14,151 13,115 16,649 36,280 49,290
Table 16 Current and future cost of (CHF 000,000) osteoporosis (ex-
cluding value of QALYs lost) by age and calendar year in men and
women in Switzerland
2010 2015 2020 2025
Women
50–74 366 396 415 444
75+ 1,095 1,167 1,250 1,353
All 1,461 1,563 1,665 1,797
Men
50–74 298 324 348 377
75+ 291 339 401 468
All 588 663 749 845
Women and men
50–74 664 719 763 821
75+ 1,386 1,506 1,651 1,821
All 2,050 2,226 2,414 2,642
Table 17 Projected QALYs lost due to incident and prior fractures for the
year 2010 and 2025 by age in men and women in Switzerland
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 2,301 2,839 2,248 2,459 4,549 5,298
75+ 5,025 6,430 6,760 7,544 11,785 13,974
All 7,327 9,269 9,007 10,003 16,334 19,271
Men
50–74 2,090 2,696 1,939 2,254 4,029 4,950
75+ 1,468 2,517 1,996 2,724 3,464 5,241
All 3,558 5,213 3,935 4,978 7,493 10,191
Women and men
50–74 4,391 5,535 4,187 4,713 8,578 10,248
75+ 6,494 8,947 8,756 10,268 15,249 19,215
All 10,885 14,482 12,943 14,981 23,827 29,463
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the fracture site. The increase was estimated to be par-
ticularly marked in men (47 %) compared to women
(27 %). It should be noted that the forecasts assume
constant fracture incidence rates with time. However,
small decreases in age-adjusted incidence for hip fracture
incidence rates have been observed in recent years in
Switzerland [6, 7], potentially rendering the estimates
biased upwards.
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise fromCHF 2.1 billion in 2010 to CHF 2.6
billion in 2025, corresponding to an increase of 29 % (Ta-
ble 16). Costs incurred in women and men increased by 23
and 44 %, respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 24,000 in 2010 to 29,000 in
2025, corresponding to an increase of 24 % (Table 17).
The increase was estimated to be particularly marked in
men (36 %) compared to women (18 %). Incident and
prior fractures accounted for 64 and 36 % of the in-
crease, respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately CHF 5.3 billion
in 2010 to CHF 6.7 billion in 2025. The increase was estimat-
ed to be particularly marked in men (+39 %) compared to
women (+20 %) (Table 18).
Treatment uptake
To estimate the uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to derive
the number of defined daily doses (DDDs) sold per 100,000
persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an esti-
mation of the proportion of the population aged 50 years or
above who received any osteoporosis treatment (see Chapter 5
of the report “Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden” for further
Table 18 Present and future cost (CHF 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Switzerland assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 985 1,048 1,096 1,165
75+ 2,699 2,858 3,032 3,255
All 3,684 3,906 4,129 4,419
Men
50–74 846 906 972 1,051
75+ 762 858 999 1,181
All 1,608 1,764 1,971 2,232
Women and men
50–74 1,831 1,954 2,068 2,216
75+ 3,461 3,716 4,032 4,436
All 5,292 5,670 6,100 6,652
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Fig. 2 Treatment uptake in
Switzerland (defined daily doses
[DDDs] per 100,000 persons
aged 50 years or above)
Table 19 Number of men and
women eligible for treatment,
treated and treatment gap in 2010
Number potentially
treated (1,000s)
Number eligible for
treatment (1,000s)
Difference (1,000s) Treatment gap (%)
Men 18 28 10 36
Women 119 286 167 58
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details [1]). The proportion of persons over the age of 50 years
whowere treated increased from 1.7% in 2001 to 4.9% in 2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Switzerland were
defined as individuals with a 10-year fracture probability
exceeding that of a woman with a prior fragility fracture
derived from FRAX®, equivalent to a fracture threshold
(see Chapter 5 of the main report for further details [1]).
Subsequently, these estimates were compared to the number
of individuals who received osteoporosis treatment obtained
from the analysis of IMS Health data. The treatment gaps in
men and women were estimated at 36 and 58 %, respectively
(Table 19). Note that the estimate of the treatment gap is
conservative given that it assumes that current use of osteo-
porosis treatments is only directed to men and women at high
risk.
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